Systemtherapie des Gallenblasenkarzinoms – alles wie beim Cholangiokarzinom?

Zusammenfassung

Genomische Analysen zeigten relevante Unterschiede zwischen Gallenblasenkarzinomen und extra- sowie intrahepatischen Cholangiokarzinomen. Diese Daten haben jedoch derzeit keinen Einfluss auf die Wahl systemischer Therapieansätze. In dieser Übersicht werden zunächst Epidemiologie, Pathogenese und molekulare Charakterisierung des Gallenblasenkarzinoms dargestellt und es wird auf Unterschiede im Vergleich zum intra- und extrahepatischen Cholangiokarzinom eingegangen. Die aktuellen Optionen in der Systemtherapie des Gallenblasenkarzinoms werden diskutiert und es wird ein Ausblick auf die derzeit in der Entwicklung befindlichen Therapien gegeben.

Abstract

Recently published genomic data revealed substantial differences of gallbladder and extrahepatic as well as intrahepatic cholangiocarcinoma. However, these data have no influence on the choice of systemic therapy to date. This review shall provide a concise overview of epidemiology and pathogenesis of gallbladder carcinoma as well as the differences in the mutational profile in comparison to cholangiocarcinoma. Furthermore, the present evidence-based options in systemic therapy are discussed and a future perspective on potentially upcoming therapies is provided.

Schlüsselwörter

Gallenblasenkarzinom - Gallenwegskarzinome - Systemtherapie - Mutationsprofil

Key words

gallbladder carcinoma - biliary tract cancer - systemic therapy - mutational profile

Publication History

Received: 03 December 2019

Accepted: 20 April 2020

Article published online:
16 June 2020

• Literatur

• 1 Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer 2004; 4: 695-706 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/15343276
• 2 Abramson MA, Pandharipande P, Ruan D. et al Radical resection for T1b gallbladder cancer: a decision analysis. HPB 2009; 11: 656-663 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/20495633
• 3 Aloia TA, Járufe N, Javle M. et al Gallbladder Cancer: expert consensus statement. HPB 2015; 17: 681-690 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/26172135
• 4 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7-30 . Im Internet: http://doi.wiley.com/10.3322/caac.21387
• 5 Valle JW, Borbath I, Khan SA. et al Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 2016; 27: v28-v37 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/27664259
• 6 Sharma A, Sharma KL, Gupta A. et al Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update. World J Gastroenterol 2017; 23: 3978-3998 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/28652652
• 7 Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Sonderauswertung Datengrundlage Mortalität: Todesursachenstatistik. 2020 Im Internet: https://www.destatis.de/de/methoden/qualitaet/qualitaetsberichte/gesundheit/todesursachen
• 8 Nir I, Wiggins CL, Morris K. et al Diversification and trends in biliary tree cancer among the three major ethnic groups in the state of New Mexico. Am J Surg 2012; 203: 361-365 . Im Internet: https://www.sciencedirect.com/science/article/abs/pii/S0002961011007495
• 9 Goldin RD, Roa JC. Gallbladder cancer: A morphological and molecular update. Histopathology 2009; 55: 218-229
• 10 Miller G, Jarnagin WR. Gallbladder carcinoma. Eur J Surg Oncol 2008; 34: 306-312
• 11 Zatonski WA, Przewozniak K, Lowenfels AB. et al Epidemiologic Aspects of Gallbladder Cancer: A Case-Control Study of the SEARCH Program of the International Agency for Research on Cancer. JNCI J Natl Cancer Inst 1997; 89: 1132-1138 . Im Internet: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/89.15.1132
• 12 Larsson SC, Wolk A. Obesity and the risk of gallbladder cancer: a meta-analysis. Br J Cancer 2007; 96: 1457-1461 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/17375043
• 13 Lai HC, Chang SN, Lin CC. et al Does diabetes mellitus with or without gallstones increase the risk of gallbladder cancer? Results from a population-based cohort study. J Gastroenterol 2013; 48: 856-865 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/23065035
• 14 Pilgrim CHC, Groeschl RT, Christians KK. et al Modern perspectives on factors predisposing to the development of gallbladder cancer. HPB 2013; 15: 839-844 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/23458506
• 15 Iyer P, Barreto SG, Sahoo B. et al Non-typhoidal Salmonella DNA traces in gallbladder cancer. Infect Agent Cancer 2016; 11: 12 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/26941832
• 16 Everson GT, McKinley C, Kern Jr F. Mechanisms of gallstone formation in women. Effects of exogenous estrogen (Premarin) and dietary cholesterol on hepatic lipid metabolism. J Clin Invest 1991; 87: 237-246 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/1845870
• 17 Jackson, Heidi H, Glasgow, Robert, Mulvihill, Sean, Cannon-Albright LA. Familial risk in gallbladder cancer. J Am Coll Surg 2007; 205: S38
• 18 Hemminki K, Li X. Familial liver and gall bladder cancer: A nationwide epidemiological study from Sweden. Gut 2003; 52: 592-596
• 19 Borger DR, Tanabe KK, Fan KC. et al Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping. Oncologist 2012; 17: 72-79 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/22180306
• 20 Nakamura H, Arai Y, Totoki Y. et al Genomic spectra of biliary tract cancer. Nat Genet 2015; 47: 1003-1010 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/26258846
• 21 Albrecht T, Rausch M, Roessler S. et al HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma. Virchows Arch 2019; DOI: 10.1007/s00428-019-02706-610.1007/s00428-019-02706-6. [Epub ahead of print]
• 22 Kim Y, Bang SS, Jee S. et al Prevalence and Clinicopathological Significance of MET Overexpression and Gene Amplification in Patients with Gallbladder Carcinoma. Cancer Res Treat 2020; 52: 481-491
• 23 Chang HJ, Kim SW, Kim YT. et al Loss of heterozygosity in dysplasia and carcinoma of the gallbladder. Mod Pathol 1999; 12: 763-769
• 24 Jain K, Mohapatra T, Das P. et al Sequential occurrence of preneoplastic lesions and accumulation of loss of heterozygosity in patients with gallbladder stones suggest causal association with gallbladder cancer. Ann Surg 2014; 260: 1073-1080
• 25 Fuks D, Regimbeau JM, Le Treut YP. et al Incidental Gallbladder Cancer by the AFC-GBC-2009 Study Group. World J Surg 2011; 35: 1887-1897 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/21547420
• 26 Duffy A, Capanu M, Abou-Alfa GK. et al Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol 2008; 98: 485-489 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/18802958
• 27 Ethun CG, Le N, Lopez-Aguiar AG. et al Pathologic and Prognostic Implications of Incidental versus Nonincidental Gallbladder Cancer: A 10-Institution Study from the United States Extrahepatic Biliary Malignancy Consortium. Am Surg 2017; 83: 679-686 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/28738935
• 28 Glimelius B, Hoffman K, Sjoden PO. et al Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/8879373
• 29 Dingle BH, Rumble RB, Brouwers MC. et al The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review. Can J Gastroenterol 2005; 19: 711-716 . Im Internet: http://www.hindawi.com/journals/cjgh/2005/565479/abs/
• 30 Valle. ABC-02. CDDP+GEM vs GEM for biliary tract cancer. OS better with CDDP+GEM. NEJM 2010; 4: 395-397 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/20678012
• 31 Okusaka T, Nakachi K, Fukutomi A. et al Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103: 469-474 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/20628385
• 32 Valle JW, Furuse J, Jitlal M. et al Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 2014; 25: 391-398 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/24351397
• 33 Sharma A, Dwary AD, Mohanti BK. et al Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study. J Clin Oncol 2010; 28: 4581-4586 . Im Internet: http://ascopubs.org/doi/10.1200/JCO.2010.29.3605
• 34 Valle JW, Borbath I, Khan SA. et al Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 2016; 27: v28-v37 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/27664259
• 35 Lamarca A, Hubner RA, David Ryder W. et al Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 2014; 25: 2328-2338 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/24769639
• 36 Sakai D, Kanai M, Kobayashi S. et al 615ORandomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). Ann Oncol 2018; 29 (Suppl. 08) viii205 . Im Internet: https://academic.oup.com/annonc/article/doi/10.1093/annonc/mdy282/5140253
• 37 Shroff RT, Javle MM, Xiao L. et al Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers. JAMA Oncol 2019; 5: 824 . Im Internet: http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2019.0270
• 38 Adeva J, Sangro B, Salati M. et al Medical treatment for cholangiocarcinoma. Liver Int 2019; 39 (Suppl. 01) 123-142 . Im Internet: https://onlinelibrary.wiley.com/doi/abs/10.1111/liv.14100
• 39 Roa I, de Toro G, Schalper K. et al Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer. Gastrointest Cancer Res 2014; 7: 42-48 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/24799970
• 40 Javle M, Churi C, Kang HC. et al HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol 2015; 8: 58 . Im Internet: https://jhoonline.biomedcentral.com/articles/10.1186/s13045-015-0155-z
• 41 Goeppert B, Roessler S, Renner M. et al Low frequency of mismatch repair deficiency in gallbladder cancer. Diagn Pathol 2019; 14: 36 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/31068195
• 42 Winkelmann R, Schneider M, Hartmann S. et al Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital. Int J Mol Sci 2018; 19: 1421 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/29747443
• 43 Kim RD, Kim DW, Alese OB. et al A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC). J Clin Oncol 2019; 37: 4097-4097 . Im Internet: https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.4097
• 44 Ueno M, Ikeda M, Morizane C. et al Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol 2019; 4: 611-621 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/31109808
• 45 Strauss J, Heery CR, Schlom J. et al Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors. Clin Cancer Res 2018; 24: 1287-1295 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/29298798
• 46 Czink E, Kloor M, Goeppert B. et al Successful immune checkpoint blockade in a patient with advanced stage microsatellite unstable biliary tract cancer. Cold Spring Harb Mol Case Stud 2017; 3: mcs.a001974 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/28619747
• 47 Piehler JM, Crichlow RW. Primary carcinoma of the gallbladder. Surg Gynecol Obstet 1978; 147: 929-942 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/362580
• 48 Diehl AK. Gallstone size and the risk of gallbladder cancer. JAMA 1983; 250: 2323-2326 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/6632129
• 49 Redaelli CA, Büchler MW, Schilling MK. et al High coincidence of Mirizzi syndrome and gallbladder carcinoma. Surgery 1997; 121: 58-63 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/9001552
• 50 Eslick GD. Epidemiology of Gallbladder Cancer. Gastroenterol Clin North Am 2010; 39: 307-330 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/20478488
• 51 Gutt C, Jenssen C, Barreiros AP. et al. für die Teilnehmer der Konsensuskonferenz, Deutsche Gesellschaft für Innere Medizin e. V. (DGIM), Österreichische Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH), Schweizer Gesellschaft für Gastroenterologie (SGH), Gesellschaft für Humangenetik (GfH), Deutsche Gesellschaft für Ultraschall in der Medizin (DEGUM), Deutsche Gesellschaft für Chirurgie (DGCH), Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG; beratende Funktion ohne Stimmrecht), Deutsche Arbeitsgemeinschaft zum Studium der Leber (GASL), Deutsche Röntgengesellschaft (DRG), Deutsche Leberhilfe e. V. Updated S3-Guideline for Prophylaxis, Diagnosis and Treatment of Gallstones. German Society for Digestive and Metabolic Diseases (DGVS) and German Society for Surgery of the Alimentary Tract (DGAV) – AWMF Registry 021/008. Z Gastroenterol 2018; 56: 912-966 . Im Internet: http://www.thieme-connect.de/DOI/DOI?10.1055/a-0644-2972
• 52 Tanaka K, Ikoma A, Hamada N. et al Biliary tract cancer accompanied by anomalous junction of pancreaticobiliary ductal system in adults. Am J Surg 1998; 175: 218-220 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/9560123
• 53 Lewis JT, Talwalkar JA, Rosen CB. et al Prevalence and Risk Factors for Gallbladder Neoplasia in Patients With Primary Sclerosing Cholangitis: Evidence for a Metaplasia-Dysplasia-Carcinoma Sequence. Am J Surg Pathol 2007; 31: 907-913 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/17527079
• 54 Stephen AE, Berger DL. Carcinoma in the porcelain gallbladder: A relationship revisited. Surgery 2001; 129: 699-703 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/11391368
• 55 Hale MD, Roberts KJ, Hodson J. et al Xanthogranulomatous cholecystitis: a European and global perspective. HPB 2014; 16: 448-458 . Im Internet: https://www.sciencedirect.com/science/article/pii/S1365182X15315847
• 56 Dutta U, Garg PK, Kumar R. et al Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. Am J Gastroenterol 2000; 95: 784-787 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/10710075
• 57 Dorjgochoo T, Shu XO, Li HL. et al Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer 2009; 124: 2442-2449 . Im Internet: http://www.ncbi.nlm.nih.gov/pubmed/19170208
• 58 Sondka Z, Bamford S, Cole CG. et al The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat Rev Cancer 2018; 18: 696-705 . Im Internet: http://www.nature.com/articles/s41568-018-0060-1